Alcon
ALC
Market cap $43.3B

87.48 USD

-1.22

1.38%

At close Jul 11, 4:00 PM EDT

After hours

87.49

+0.01

0.01%

1 day

-1.38%

5 days

0.05%

1 month

-1.24%

3 months

-2.38%

6 months

4.90%

Year to date

4.83%

1 year

-3.38%

5 years

55.22%

10 years

50.72%

About: Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

Employees: 25,599

Healthcare Medical Instruments & Supplies

0

Funds holding %

of 7,312 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 15 (+3) [Q1 2025]

13% more first-time investments, than exits

New positions opened: 79 | Existing positions closed: 70

10% more capital invested

Capital invested by funds: $22.2B [Q4 2024] → $24.5B (+$2.29B) [Q1 2025]

1% less funds holding

Funds holding: 645 [Q4 2024] → 641 (-4) [Q1 2025]

10% less repeat investments, than reductions

Existing positions increased: 196 | Existing positions reduced: 217

3.0% less ownership

Funds ownership: 53.07% [Q4 2024] → 50.07% (-3.0%) [Q1 2025]

33% less call options, than puts

Call options by funds: $226M | Put options by funds: $340M

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$110

26%

upside

Avg. target

$110

26%

upside

High target

$110

26%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Needham

David Saxon

26%upside

$110

Buy

Reiterated

14 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about ALC published over the past 30 days

Zacks Investment Research

Alcon Stock Gains Following UNITY VCS' Approval in Canada

ALC's UNITY VCS gets Canada's approval, advancing surgical precision with faster, more efficient technology.

Alcon Stock Gains Following UNITY VCS' Approval in Canada

Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. “Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who help.

Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval

Zacks Investment Research

Is it Apt to Retain Alcon Stock in Your Portfolio for Now?

ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.

Is it Apt to Retain Alcon Stock in Your Portfolio for Now?

Alcon Canada Earns Global Recognition as a Top Employer

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced that Alcon Canada has been certified as a Top Employer in Canada by the Top Employers Institute, a recognized authority on identifying excellence in people practices and workplace culture. Being certified as a Top Employer showcases Alcon Canada's commitment to building a better world of work through exceptional HR policies and forward-thinking people practices. This recog.

Alcon Canada Earns Global Recognition as a Top Employer

Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System

Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years Dr. Echegoyen Participated in Clinical Trials for the First Major Phacoemulsification Advancement in Over 15 Years

Gordon Schanzlin New Vision Institute Becomes First U.S. Clinic to Use Alcon's Breakthrough Unity Phaco System

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

TORONTO--(BUSINESS WIRE)-- #AlconCanada--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon® PanOptix® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL.1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theore.

Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each.

LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR

Zacks Investment Research

Alcon Stock Rises Following the FDA Approval of TRYPTYR

FDA approves ALC's TRYPTYR, a new dry eye treatment with rapid tear production. The approval is supported by strong Phase 3 trial results.

Alcon Stock Rises Following the FDA Approval of TRYPTYR

US FDA approves Alcon's new dry-eye drug

Eye-care drugmaker Alcon said on Wednesday that the U.S. Food and Drug Administration has approved its treatment for dry eye disease (DED).

US FDA approves Alcon's new dry-eye drug

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

GENEVA--(BUSINESS WIRE)--Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease.

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease

See News Rankings

Charts implemented using Lightweight Charts™